Amylyx Pharmaceuticals, Inc. (AMLX)Healthcare | Drug Manufacturers - Specialty & Generic | Cambridge, United States | NasdaqGS
27.48 USD
-0.66
(-2.345%) ⇩
(Oct. 12, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 7:50 a.m. EDT
The investment case for Amylyx is currently paralyzed by a severe disconnect between its explosive recent recovery and its deteriorating financial reality. While the stock has rallied over 300% year-to-date, the underlying business remains in a deep hole with negative free cash flow, negative operating cash flow, and a trailing EPS of minus $1.41. The balance sheet is fragile, with a massive operating burn rate that threatens to deplete the modest cash pile unless the pipeline delivers immediate commercial success. The recent price surge appears to be a speculative reaction to the Avexitide drug outlook rather than a correction of fundamental value, as the company still lacks the profitability metrics required for a high-quality compounder. Consequently, the short-term outlook is volatile and directionless, caught between the momentum of the rally and the drag of the losses, while the long-term thesis remains unproven given the lack of sustained revenue growth and the continued reliance on capital markets for survival. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.350289 |
| MSTL | 0.425271 |
| AutoARIMA | 0.429386 |
| AutoETS | 0.429389 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 26% |
| H-stat | 16.24 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.131 |
| Excess Kurtosis | -1.47 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 2.197 |
| Market Cap | 3,449,098,496 |
| Forward P/E | -23.93 |
| Beta | -0.09 |
| Website | https://amylyx.com |
As of Oct. 10, 2026, 7:50 a.m. EDT: Options activity reveals a distinct divergence between near-term and medium-term sentiment. In the October 2026 expiration, there is aggressive new buying of out-of-the-money calls at strikes $36 and $38, suggesting a speculative bet on a sharp spike toward $40+. However, this is immediately countered by massive open interest in deep out-of-the-money puts ($35 strike) and significant volume in the December 2026 expiration at lower strikes ($22), indicating a hedge against a drop to the $20s. The implied volatility surface shows elevated premiums for both extremes, reflecting a 'long gamma' environment where the market is pricing in a binary outcome rather than a steady trend.
| Attribute | Value |
|---|---|
| 52 Week Change | 0.93657506 |
| Address1 | 55 Cambridge Parkway |
| Address2 | Suite 6W |
| All Time High | 41.93 |
| All Time Low | 1.575 |
| Ask | 34.68 |
| Ask Size | 2 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.2 - Strong Buy |
| Average Daily Volume10 Day | 1,422,770 |
| Average Daily Volume3 Month | 2,351,823 |
| Average Volume | 2,351,823 |
| Average Volume10Days | 1,422,770 |
| Beta | -0.092 |
| Bid | 20.37 |
| Bid Size | 2 |
| Board Risk | 7 |
| Book Value | 2.148 |
| City | Cambridge |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 8 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 27.48 |
| Current Ratio | 12.12 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 28.49 |
| Day Low | 27.4 |
| Debt To Equity | 2.197 |
| Display Name | Amylyx Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,017,600 |
| Earnings Call Timestamp Start | 1,786,017,600 |
| Earnings Timestamp | 1,786,019,400 |
| Earnings Timestamp End | 1,793,881,800 |
| Earnings Timestamp Start | 1,793,881,800 |
| Ebitda | -161,734,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -17.414 |
| Enterprise Value | 2,816,400,384 |
| Eps Current Year | -1.49716 |
| Eps Forward | -1.14844 |
| Eps Trailing Twelve Months | -1.41 |
| Esg Populated | 0 |
| Exchange | NMS |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 30.2879 |
| Fifty Day Average Change | -2.8079014 |
| Fifty Day Average Change Percent | -0.09270703 |
| Fifty Two Week Change Percent | 93.65751 |
| Fifty Two Week High | 41.14 |
| Fifty Two Week High Change | -13.66 |
| Fifty Two Week High Change Percent | -0.33203694 |
| Fifty Two Week Low | 10.83 |
| Fifty Two Week Low Change | 16.65 |
| Fifty Two Week Low Change Percent | 1.5373961 |
| Fifty Two Week Range | 10.83 - 41.14 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,641,565,800,000 |
| Float Shares | 97,276,778 |
| Forward Eps | -1.14844 |
| Forward P E | -23.92811 |
| Free Cashflow | -77,316,376 |
| Full Exchange Name | NasdaqGS |
| Full Time Employees | 136 |
| Fullday Change | -0.049999237 |
| Fullday Change Percent | -0.18194774 |
| Fullday Price | 27.43 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,790,812,800 |
| Gross Margins | 0.0 |
| Gross Profits | -92,447,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.07157 |
| Held Percent Institutions | 0.92434 |
| Implied Shares Outstanding | 125,513,048 |
| Industry | Drug Manufacturers - Specialty & Generic |
| Industry Disp | Drug Manufacturers - Specialty & Generic |
| Industry Key | drug-manufacturers-specialty-generic |
| Ipo Expected Date | 2,022-01-07 |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | Amylyx Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, engages in the discovery and development of treatment options for neurodegenerative diseases and endocrine conditions in the United States. It provides Avexitide, an investigational, first-in-class glucagon-like peptide-1, or GLP-1 receptor antagonist, which is in phase 3 clinical trial to treat post-bariatric hypoglycemia and congenital hyperinsulinism. The company also develops AMX0035, an oral, fixed-dose combination of sodium phenylbutyrate and taurursodiol which is phase 2 clinical trial for the treatment of wolfram syndrome, as well as in phase 2b/3 clinical trial to treat progressive supranuclear palsy; AMX0114, which is in phase 1 clinical trial for the treatment of amyotrophic lateral sclerosis; and long-acting GLP-1 receptor antagonist to treat post-bariatric hypoglycemia and other rare diseases. Further, it develops AMX0318, a GLP-1 receptor antagonist for the treatment of post-bariatric hypoglycemia and other rare diseaees. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts. |
| Long Name | Amylyx Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 3,449,098,496 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_317169670 |
| Most Recent Quarter | 1,782,777,600 |
| Net Income To Common | -152,092,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 4,141,930,584 |
| Number Of Analyst Opinions | 11 |
| Open | 28.04 |
| Operating Cashflow | -126,577,000 |
| Operating Margins | 0.0 |
| Overall Risk | 7 |
| Payout Ratio | 0.0 |
| Phone | 617 682 0917 |
| Pre Market Change | -0.049999237 |
| Pre Market Change Percent | -0.18194774 |
| Pre Market Price | 27.43 |
| Pre Market Time | 1,791,893,058 |
| Previous Close | 28.14 |
| Price Eps Current Year | -18.354752 |
| Price Hint | 2 |
| Price To Book | 12.793296 |
| Profit Margins | 0.0 |
| Quick Ratio | 11.88 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.16667 |
| Region | US |
| Regular Market Change | -0.66 |
| Regular Market Change Percent | -2.34542 |
| Regular Market Day High | 28.49 |
| Regular Market Day Low | 27.4 |
| Regular Market Day Range | 27.4 - 28.49 |
| Regular Market Open | 28.04 |
| Regular Market Previous Close | 28.14 |
| Regular Market Price | 27.48 |
| Regular Market Time | 1,791,835,202 |
| Regular Market Volume | 1,106,088 |
| Return On Assets | -0.4413 |
| Return On Equity | -0.7473 |
| Sand P52 Week Change | 0.17502642 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 8 |
| Shares Outstanding | 125,513,048 |
| Shares Percent Shares Out | 0.1009 |
| Shares Short | 12,666,971 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 12,737,201 |
| Short Name | Amylyx Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.12640001 |
| Short Ratio | 8.18 |
| Source Interval | 15 |
| State | MA |
| Symbol | AMLX |
| Target High Price | 57.0 |
| Target Low Price | 20.0 |
| Target Mean Price | 42.36364 |
| Target Median Price | 42.0 |
| Total Cash | 250,760,000 |
| Total Cash Per Share | 2.251 |
| Total Debt | 5,255,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 18.981874 |
| Two Hundred Day Average Change | 8.498125 |
| Two Hundred Day Average Change Percent | 0.44769683 |
| Type Disp | Equity |
| Volume | 1,106,088 |
| Website | https://amylyx.com |
| Zip | 2,142 |